| MEIP Stock | | | USD 5.92 1.42 31.56% |
The current 90-days correlation between MEI Pharma and Kezar Life Sciences is -0.04 (i.e., Good diversification). The correlation of MEI Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
MEI Pharma Correlation With Market
Significant diversification
The correlation between MEI Pharma and DJI is 0.08 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding MEI Pharma and DJI in the same portfolio, assuming nothing else is changed.
Check out
Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MEI Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in gross domestic product.
To learn how to invest in MEI Stock, please use our
How to Invest in MEI Pharma guide.
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.
High positive correlations | KZR | | ELDN | | NXTC | | KZR | | VSTM | | NXTC | | VSTM | | ELDN |
| | High negative correlations |
Risk-Adjusted IndicatorsThere is a big difference between MEI Stock performing well and MEI Pharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze MEI Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.